A financial perspective on the pharmaceutical industry

Yunus Emre Kahraman; Yılmaz Çalışkan

doi:10.56782/pps.180

Published : 2024-03-07

Vol. 22 No. 1 (2024)

A financial perspective on the pharmaceutical industry

Yunus Emre Kahraman

Yılmaz Çalışkan

DOI: https://doi.org/10.56782/pps.180

Abstract

As a result of the epidemics in the world in recent years the importance of the health sector has once again emerged and countries have started to invest more in the health sector. In addition to developed countries, underdeveloped and developing countries are investing more in the health sector and technology and governments are trying to control increasing health expenditures. One of the important and dynamic sub-sectors of the health sector is the pharmaceutical sector. States and international companies are investing more in the pharmaceutical sector in order to combat the epidemics in recent years and are conducting more R&D studies by utilizing the developing technology. In this study in the light of the data published by the OECD, it is examined whether there is a similar relationship between the change in the share of health expenditures in the GNP (Gross National Product) of OECD countries between 2010 and 2022 and the change in the size of the pharmaceutical sector in OECD countries. The change in the size of the pharmaceutical sector and the change in the share of health expenditures in GNP have not yielded similar results in each OECD country. It is thought that different factors such as demographic characteristics, geographical location and economic conditions of countries should be taken into consideration when evaluating the relationship between these two variables.

Keywords:

Pharmaceuticals, Public Health, Finance, Financial Markets

Similar Articles

Mateusz Sobczyk, Mikołaj Porzak, Daria Żuraw, Alicja Sodolska, Paulina Oleksa, Kacper Jasiński, Small intestinal bacterial overgrowth – current, novel and possible future methods of treatment and diagnosis , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Girish B S, Srinivasan R, Joel M. Johns, C S Meghana, Adaptability of clinical pharmacist led interventions in the management of anemia of chronic renal disease: optimizing care , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)

<< < 1 2 3 4 5 6

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Kahraman, Y. E., & Çalışkan, Y. (2024). A financial perspective on the pharmaceutical industry. Prospects in Pharmaceutical Sciences, 22(1), 23–31. https://doi.org/10.56782/pps.180

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Yumuşak,. İ.G.; Yıldırım, D. Ç. Sağlık Harcamaları İktisadi Büyüme İlişkisi Üzerine Ekonometrik Bir İnceleme. Bilgi Ekonomisi ve Yönetimi Dergisi 2009, 4(1), 57-70.

Mutlu, A. ; Işık, A. Sağlık Ekonomisine Giriş. Ekin Yayınları: Bursa, Türkiye, 2005, ISBN 9786055335991

Bölükbaşı, N.; Işık, H.; Söyler, S. OECD Ülkelerinde İlaç Harcamaları ile Sağlık Harcamaları. Hekim ve Hemşirelik Mezunları Arasındaki İlişkilerin İncelenmesi. Ekonomi İşletme Siyaset ve Uluslararası İlişkiler Dergisi (JEBPIR). 2020, 6, 223-231.

Wainwright, D. The Changing Face of Medical Sociology. A Sociology of Health. SAGE Publications: London, United Kingdom, 2008, ISBN 9781412921589 DOI: https://doi.org/10.4135/9781446213575

Özdemir, B. Türkiye'de İlaç Pazarının Analizi ve Ekonomi Üzerine Etkisi. Niğde: Niğde Ömer Halisdemir Üniversitesi. Sosyal Bilimler Enstitüsü. Türkiye, 2019.

Mikulic, M. Global Pharmaceutical Industry - Statistics & Facts. Available online: https://www.statista.com/topics/1764/global-pharmaceutical-industry/#topicOverview. (Date of Access: 2024-01-15)

Zhang, W. Pharmaceutical industry in China - statistics & facts. Available online: https://www.statista.com/topics/5001/pharmaceutical-industry-in-china/#topicOverview. (Date of Access: 2024-01-01)

Salib, V. Comparing Global Pharmaceutical Markets: US. UK. and China. Pharmanews Intelligence 07.02.2023. Available online: https://pharmanewsintel.com/features/comparing-global-pharmaceutical-markets-the-us-uk-and-china. (Date of Access: 2023-12-18)

Hernandez, I.; San-Juan-Rodriguez, A; Good, C. B.; Gellad, W. F. Changes in List Prices. Net Prices and Discounts for Branded Drugs in the US, 2007–2018. JAMA 2020, 323(9), 854-862. DOI: 10.1001/jama.2020.1012 DOI: https://doi.org/10.1001/jama.2020.1012

Kapczynski, A. The Political Economy of Market Power in Pharmaceuticals. J. Health Polit. Policy Law. 2023, 48(2), 215-239. DOI: 10.1215/03616878-10234184 DOI: https://doi.org/10.1215/03616878-10234184

Gostin, L. O. Biden’s Plan to Vaccinate the World Won’t Work. Here’s a Better One. Washington Post. 27. 09. 2021. Available online: https://www.washingtonpost.com/outlook/2021/09/27/biden-vaccines-globe-inequity-donations/.[Date of Access: 2023-12-30]

Vogler, S.; Habl, C; Leopold, C; Mazag, J,; Morak, S.; Zimmerman, N. PHIS Pharmaceutical Health Information system. Hospital Pharma Report 2010. 05 .2010. Available online: https://webgate.ec.europa.eu/chafea_pdb/assets/files/pdb/2007333/2007333_phis_hospital_pharma_rep. (Date of Access: 2024-01-01).

Carone, G.; Schwierz, C.; Xavier, A. Cost-containment Policies in Public Pharmaceutical Spending in the EU. Economic Papers 2012, 461. Available online: https://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf.(Date of Access:2024-01-01) DOI: https://doi.org/10.2139/ssrn.2161803

Kanavos, P.; Seeley, L.; Vandoros, S. Tender Systems for Outpatient Pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. 10.2009. Available online: https://www.politico.eu/wp-content/uploads/2019/02/Tender-systems-for-outpatient-pharmaceuticals-in-the-EU.pdf. [Date of Access: 2024-01-01]

Garcia-Goni, M. Rationalizing Pharmaceutical Spending. 2022. Available online: https://www.elibrary.imf.org/view/journals/001/2022/190/article-A001-en.xml?ArticleTabs=fulltext. eISBN: 9798400219849 [Date of Access: 2024-01-01] DOI: https://doi.org/10.5089/9798400219849.001

Danzon, P. M.; Mulcahy, A. W. ; Towse, A. K. Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition. and Procurement. Health Economics 2015, 24(2), 238-252. DOI: 10.1002/hec.3013 DOI: https://doi.org/10.1002/hec.3013

Wirtz, V. J.; Hogerzeil, H. V.; Gray, A. L.; Bigdeli, M.; De Joncheere, C. P.; Ewen, M. A. Essential Medicines for Universal Health Coverage. The Lancet 2017, 389(10067), 403-476. DOI: https://doi.org/10.1016/S0140-6736(16)31599-9

Bonnifield, R. S.; Keller, J. M.; Glasman, A.; Chalkidaou, K. Tackling the Triple Transition in Global Health Procurement. Center for Global Development Reports 2019. Available online: https://www.cgdev.org/better-health-procurement (Date of Access: 2024-01-01]

Kaplan, A. W.; Ritz, L. S.; Vitello, M.; Wirtz, V. J. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy 2012, 106(3), 211-224. DOİ: 10.1016/j.healthpol.2012.04.015 DOI: https://doi.org/10.1016/j.healthpol.2012.04.015

Hoen, E. The global politics of pharmaceutical monopoly power. Drug patents, access, innovation and the application of the WTO Doha Declaration on TRIPS and Public Health. AMB Publishers, Diemen, The Netherlands, 2009. ISBN 97890 79700 06 6

Kesselheim, A. S.; Avorn, J.; Sarpatwari, A. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA, 2016, 316(8), 858-871. DOİ: 10.1001/jama.2016.11237 DOI: https://doi.org/10.1001/jama.2016.11237

Mulcahy, A. W.; Whaley, C. M.; Gizaw, M.; Schwam, D.; Edenfield, N.; Becerra-Ornelas, A. U.International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies. RAND Corporation: Research Report 2021. DOI: https://doi.org/10.7249/RR2956. Available online: https://www.rand.org/pubs/research_reports/RR2956.html. (Date of Access:2023-12-29)

IMF. World Economic Outlook Slowing Growth, Rising Risks. (September 2011). Washington. Available online: https://www.imf.org/en/Publications/WEO/Issues/2016/12/31/Slowing-Growth-Rising-Risks. (Date of Access: 2023-12-16).

OECD.Stat. Available online: https://stats.oecd.org/index.aspx?r=756968&lastaction=login_submit#. (Date of Access: 2023-12-26).

Yunus Emre Kahraman

yunusemrekahraman@osmaniye.edu.tr

Affiliation:

Department of Pharmacy Services, Health Services Vocational School, Osmaniye Korkut Ata University, 80-000 Osmaniye, Türkiye Turkey

Yılmaz Çalışkan

yilmazcaliskan1983@gmail.com

Affiliation:

Fethiye National Estate Directorate, Muğla Provincial Directorate Of Environment, Urbanization And Climate Change, 48300, Muğla, Türkiye Turkey